X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Biogen bolster its neuromuscular and rare disease portfolio by gaining FDA-approved Skyclarys (omaveloxolone), the first and only approved treatment for Friedreich’s ataxia (FA) in the United States.
Lead Product(s): Omaveloxolone
Therapeutic Area: Genetic Disease Product Name: Skyclarys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: $7,300.0 million Upfront Cash: $7,300.0 million
Deal Type: Acquisition September 26, 2023
Details:
Through the acquisition, Biogen bolster its neuromuscular and rare disease portfolio by gaining FDA-approved Skyclarys (omaveloxolone), the first and only approved treatment for Friedreich’s ataxia (FA) in the United States.
Lead Product(s): Omaveloxolone
Therapeutic Area: Genetic Disease Product Name: Skyclarys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: $7,300.0 million Upfront Cash: $7,300.0 million
Deal Type: Acquisition July 28, 2023
Details:
Skyclarys™ (omaveloxolone) have been shown to activate the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathways and indicated for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.
Lead Product(s): Omaveloxolone
Therapeutic Area: Genetic Disease Product Name: Skyclarys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
Skyclarys™ (omaveloxolone) have been shown to activate the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathways and indicated for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.
Lead Product(s): Omaveloxolone
Therapeutic Area: Genetic Disease Product Name: Skyclarys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
RTA 402 (bardoxolone methyl) is a small-molecule compound licensed from Reata Pharmaceuticals has been designated as a "SAKIGAKE Designation" program for the treatment of diabetic kidney disease, a Phase III clinical study for the indication in Japan.
Lead Product(s): Bardoxolone Methyl
Therapeutic Area: Nephrology Product Name: RTA 402
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Kyowa Kirin
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Details:
Skyclarys™ (omaveloxolone) have been shown to activate the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress.
Lead Product(s): Omaveloxolone
Therapeutic Area: Genetic Disease Product Name: Skyclarys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
Omaveloxolone is an investigational, oral, once-daily activator of Nrf2, a transcription factor that induces molecular pathways that promote resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling.
Lead Product(s): Omaveloxolone
Therapeutic Area: Genetic Disease Product Name: RTA 408
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2022
Details:
RTA 408 (omaveloxolone) is investigational, oral, once-daily activator of Nrf2, transcription factor that induces molecular pathways that promote resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, inhibiting pro-inflammatory signaling.
Lead Product(s): Omaveloxolone
Therapeutic Area: Genetic Disease Product Name: RTA 408
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2022
Details:
RTA 408 (Omaveloxolone) is investigational, oral, once-daily activator of Nrf2, a transcription factor that induces molecular pathways that promote resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, inhibiting pro-inflammatory signaling.
Lead Product(s): Omaveloxolone
Therapeutic Area: Genetic Disease Product Name: RTA 408
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Omaveloxolone is an investigational, oral, once-daily, activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, & inhibiting pro-inflammatory signaling.
Lead Product(s): Omaveloxolone
Therapeutic Area: Genetic Disease Product Name: RTA 408
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
